Transcriptomic change of ARDI1A mutant bladder cancer cell line treated with CPI-0209 or induced ARID1A expression

Transcriptomic change of bladder cancer cell lines treated with CPI-0209 [2]

Epigenomic change of ARDI1A mutant bladder cancer cell line treated with CPI-0209 or induced ARID1A expression

Xenograft of bladder cancer cell line HT1376 were treated with or without EZH2 inhibitors before subject to RNA-seq

Epigenomic profile of bladder cancer cell line HT1376 treated with CPI-0209

Study of CPI-0209 in patients with advanced tumors.

Comprehensive target engagement by EZH2 inhibitor CPI-0209 allows for preferential targeting of ARID1A mutant urothelial carcinoma

lncRNA expressions of the kidney tissues of DKD patients and controls

Distinct DNA methylation landscape between pediatric brain and adult brain

Chromatin reorganization drives expression of functional maturation genes in senescent pancreatic beta cells (Series1 - Transcriptome)

Chromatin reorganization drives expression of functional maturation genes in senescent pancreatic beta cells (Series2 - chromatin sccessibility, ATAC-seq)

Chromatin reorganization drives expression of functional maturation genes in senescent pancreatic beta cells (Series3 - Chromatin profiles, ChIP-seq)

Chromatin reorganization drives expression of functional maturation genes in senescent pancreatic beta cells (Series4- chromatin profiles, MINT-ChIP)

Chromatin reorganization drives expression of functional maturation genes in senescent pancreatic beta cells

Ancestralization of the modern human aryl hydrocarbon receptor by genome editing

RNA-Seq of WT and UBQLN1 KO hESCs treatment with 5%O2 or NAC

Unraveling epithelial cell heterogeneity in adamantinomatous craniopharyngioma using single-cell and spatially resolved analysis

Transcriptome Analysis of CD9-overexpressing SEM Cells after Dexamethasone Treatment

Transcriptomic analysis of human naive B cells stimulated by CD40L, CpG, anti-IgM IgG, IL-4 or combinations

Mediator Kinase Inhibition Impedes Transcriptional Plasticity and Prevents Resistance to Sustained MAPK-Targeted Therapy in KRAS-Mutant Cancers